Filtered By:
Specialty: Drugs & Pharmacology
Condition: Anxiety
This page shows you your search results in order of date.
Order by Relevance | Date
Total 98 results found since Jan 2013.
The role of the indoles in microbiota-gut-brain axis and potential therapeutic targets: A focus on human neurological and neuropsychiatric diseases
Neuropharmacology. 2023 Aug 22:109690. doi: 10.1016/j.neuropharm.2023.109690. Online ahead of print.ABSTRACTAt present, a large number of relevant studies have suggested that the changes in gut microbiota are related to the course of nervous system diseases, and the microbiota-gut-brain axis is necessary for the proper functioning of the nervous system. Indole and its derivatives, as the products of the gut microbiota metabolism of tryptophan, can be used as ligands to regulate inflammation and autoimmune response in vivo. In recent years, some studies have found that the levels of indole and its derivatives differ signifi...
Source: Neuropharmacology - August 24, 2023 Category: Drugs & Pharmacology Authors: Yi Zhou Yue Chen Hui He Meichang Peng Meiqin Zeng Haitao Sun Source Type: research
The efficacy and safety of fluoxetine versus placebo for stroke recovery: a meta-analysis of randomized controlled trials
ConclusionFluoxetine improved FMMS and reduced anxiety and depression. More well-designed and large sample-size RCTs are required to further analyze the efficacy of fluoxetine in post-stroke recovery.
Source: International Journal of Clinical Pharmacy - April 20, 2023 Category: Drugs & Pharmacology Source Type: research
Esketamine ameliorates post-stroke anxiety by modulating microglial HDAC3/NF- κB/COX1 inflammatory signaling in ischemic cortex
In conclusion, this study suggests esketamine could alleviate microglial activation, reduces inflammatory cytokine, and inhibits the expression of HDAC3 and NF-κB in the cortex of PSA mice to attenuate anxiety-like behavior. Our results provided a new potential therapeutic target for applying esketamine to PSA.PMID:36997050 | DOI:10.1016/j.ejphar.2023.175667
Source: European Journal of Pharmacology - March 30, 2023 Category: Drugs & Pharmacology Authors: Ailin Huang Yang Chen Shaoshuang Wang Hailiang Du Ao Guan Huanghui Wu Qian Zhai Na Duan Xuying Li Pin Zhao Yulin Zhu Juan Bai Ye Xiao Tingting Yang Qiang Wang Bin Deng Source Type: research
Acori Tatarinowii Rhizoma: A comprehensive review of its chemical composition, pharmacology, pharmacokinetics and toxicity
Acori Tatarinowii Rhizoma (ATR, Shi Chang Pu in Chinese), a natural product with multiple targets in various diseases. This review provides the comprehensive summary of the chemical composition, pharmacological effects, pharmacokinetics parameters and toxicity of ATR. The results indicated that ATR possesses a wide spectrum of chemical composition, including volatile oil, terpenoids, organic acids, flavonoids, amino acids, lignin, carbohydrates and so on. Accumulating evidence from various studies has shown that ATR exerts a wide range of pharmacological properties, including protecting nerve cells, alleviating learning an...
Source: Frontiers in Pharmacology - March 16, 2023 Category: Drugs & Pharmacology Source Type: research
L-proline transporter inhibitor (LQFM215) promotes neuroprotection in ischemic stroke
CONCLUSIONS: This dataset suggests that the new compounds inhibit cerebral L-proline uptake and that LQFM215 promotes neuroprotection and neuro-repair in the acute ischemic stroke model.PMID:36719635 | DOI:10.1007/s43440-023-00451-x
Source: Pharmacological Reports - January 31, 2023 Category: Drugs & Pharmacology Authors: Gustavo Almeida Carvalho Raphaela Almeida Chiareli Bruno Lemes Marques Ricardo Cambraia Parreira Eric de Souza Gil Fl ávio Silva de Carvalho Andr é Luís Batista da Rocha Rafaela Ribeiro Silva Fran çois Noël Boniek Gontijo Vaz Luciano Morais Li ão Sh Source Type: research
Effects of chronic vagal nerve stimulation in the treatment of β-AMYLOID induced neuropsychiatric symptoms
In conclusion, VNS could be an effective treatment of NPSs, especially depression and anxiety, in AD patients without impairing cognition.PMID:35973478 | DOI:10.1016/j.ejphar.2022.175179
Source: European Journal of Pharmacology - August 16, 2022 Category: Drugs & Pharmacology Authors: Metin Yesiltepe Bariscan Cimen Yildirim Sara Source Type: research
Neuroprotective Potency of Neolignans in Magnolia officinalis Cortex Against Brain Disorders
In recent years, neurological diseases including Alzheimer’s disease, Parkinson’s disease and stroke are one of the main causes of death in the world. At the same time, the incidence of psychiatric disorders including depression and anxiety has been increasing. Accumulating elderly and stressed people suffer from these brain disorders, which is undoubtedly a huge burden on the modern aging society. Neolignans, the main active ingredients in Magnolia officinalis cortex, were reported to have neuroprotective effects. In addition, the key bioactive ingredients of neolignans, magnolol (1) and honokiol (2), were proved to p...
Source: Frontiers in Pharmacology - June 16, 2022 Category: Drugs & Pharmacology Source Type: research
A Comprehensive Review on Therapeutic Potential of Chrysin in Brain Related Disorders
This study depicts the relationship of chrysin with different brain related disorders and discusses the mechanisms responsible for the potential role of chrysin as a pharmacological agent for the treatment and management of different brain disorders, based on the results of several preclinical studies and taking into account the therapeutic effects of the compound.PMID:35657041 | DOI:10.2174/1871527321666220602111935
Source: CNS and Neurological Disorders Drug Targets - June 3, 2022 Category: Drugs & Pharmacology Authors: Ahsas Goyal Geetanjali Singh Aanchal Verma Source Type: research
